Polycythemia vera differential diagnosis: Difference between revisions
Line 109: | Line 109: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Chronic myeloid leukemia]] (CML) | ! align="center" style="background:#DCDCDC;" |[[Chronic myeloid leukemia]] (CML) | ||
| | | align="center" style="background:#F5F5F5;" |- | ||
| | | align="center" style="background:#F5F5F5;" |- | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* Reciprocal translocation of chromosomes 9 and 22 | * Reciprocal translocation of chromosomes 9 and 22 | ||
* Production of BCR-Abl kinase | * Production of BCR-Abl kinase | ||
| + | | align="center" style="background:#F5F5F5;" |+ | ||
| + | | align="center" style="background:#F5F5F5;" |+ | ||
| + | | align="center" style="background:#F5F5F5;" |+ | ||
|[[Abdominal pain]] | | align="center" style="background:#F5F5F5;" |[[Abdominal pain]] | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| + | | align="center" style="background:#F5F5F5;" |+ | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| + | | align="center" style="background:#F5F5F5;" |+ | ||
| | | align="center" style="background:#F5F5F5;" | | ||
|↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
|↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
|↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
|↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| | | align="center" style="background:#F5F5F5;" | | ||
|Elevated metamyelocytes and other [[white blood cells]] at various stages of maturation | | align="center" style="background:#F5F5F5;" |Elevated metamyelocytes and other [[white blood cells]] at various stages of maturation | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* [[Imatinib]] | * [[Imatinib]] | ||
* [[Dasatinib]] | * [[Dasatinib]] | ||
Line 138: | Line 138: | ||
* [[Ponatinib]] for T315I kinase domain mutation | * [[Ponatinib]] for T315I kinase domain mutation | ||
* [[Interferon-alpha]] | * [[Interferon-alpha]] | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* Can appear similar to [[leukemoid reaction]] | * Can appear similar to [[leukemoid reaction]] | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Primary myelofibrosis]] (PMF) | ! align="center" style="background:#DCDCDC;" |[[Primary myelofibrosis]] (PMF) | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* Clonal disorder of [[megakaryocytes]] | * Clonal disorder of [[megakaryocytes]] | ||
* Excess production [[TGF-beta]] and [[collagen]] | * Excess production [[TGF-beta]] and [[collagen]] | ||
| + | | align="center" style="background:#F5F5F5;" | + | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| + | | align="center" style="background:#F5F5F5;" | + | ||
|[[Abdominal pain]] | | align="center" style="background:#F5F5F5;" |[[Abdominal pain]] | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* Early satiety | * Early satiety | ||
|Pallor | | align="center" style="background:#F5F5F5;" |Pallor | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| + | | align="center" style="background:#F5F5F5;" | + | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* [[Hepatomegaly]] | * [[Hepatomegaly]] | ||
* [[Bruising]] | * [[Bruising]] | ||
|↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
|↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
|↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
|↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* [[Hydroxyurea]] | * [[Hydroxyurea]] | ||
* [[Stem cell transplant]] | * [[Stem cell transplant]] | ||
* [[Ruxolitinib]] | * [[Ruxolitinib]] | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* Variable risk for development of [[acute leukemia]] | * Variable risk for development of [[acute leukemia]] | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |Secondary polycythemia | ! align="center" style="background:#DCDCDC;" |Secondary polycythemia | ||
| - | | align="center" style="background:#F5F5F5;" |- | ||
| - | | align="center" style="background:#F5F5F5;" |- | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* [[Congestive heart failure]] (CHF) | * [[Congestive heart failure]] (CHF) | ||
* [[Interstitial lung disease]] (ILD) | * [[Interstitial lung disease]] (ILD) | ||
Line 183: | Line 183: | ||
* Chronic [[hypoxia]] | * Chronic [[hypoxia]] | ||
* Ectopic [[erythropoietin]] production from tumor (renal cell carcinoma or hepatocellular carcinoma) | * Ectopic [[erythropoietin]] production from tumor (renal cell carcinoma or hepatocellular carcinoma) | ||
| + | | align="center" style="background:#F5F5F5;" |+ | ||
| + | | align="center" style="background:#F5F5F5;" |+ | ||
| - | | align="center" style="background:#F5F5F5;" | - | ||
|Depends on etiology | | align="center" style="background:#F5F5F5;" |Depends on etiology | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* [[Shortness of breath]] | * [[Shortness of breath]] | ||
|[[Cyanosis]] | | align="center" style="background:#F5F5F5;" |[[Cyanosis]] | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* [[Crackles]] | * [[Crackles]] | ||
* [[Tachypnea]] | * [[Tachypnea]] | ||
* [[Tachycardia]] | * [[Tachycardia]] | ||
|↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="center" style="background:#F5F5F5;" | | ||
|↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="center" style="background:#F5F5F5;" | | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* Treatment of underlying cause of [[hypoxia]] | * Treatment of underlying cause of [[hypoxia]] | ||
* Supplemental oxygen | * Supplemental oxygen | ||
Line 212: | Line 212: | ||
* [[Smoking cessation]] or nicotine replacement | * [[Smoking cessation]] or nicotine replacement | ||
* Surgical removal of tumors | * Surgical removal of tumors | ||
| | | align="left" style="background:#F5F5F5;" | | ||
* Variable manifestations given the diverse etiologies | * Variable manifestations given the diverse etiologies | ||
|- | |- |
Revision as of 17:35, 20 August 2018
Polycythemia vera Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Polycythemia vera differential diagnosis On the Web |
American Roentgen Ray Society Images of Polycythemia vera differential diagnosis |
Risk calculators and risk factors for Polycythemia vera differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]; Shyam Patel [3]
Overview
Polycythemia vera must be differentiated from other myeloproliferative neoplasms, such as chronic myelogenous leukemia, essential thrombocythemia, and primary myelofibrosis. Polycythemia vera must also be differentiated from secondary polycythemia, which is usually due to chronic hypoxia. Each of these conditions have different etiologies, symptoms, laboratory abnormalities, physical exam findings, and treatments.
Differential Diagnosis
Polycythemia vera must be differentiated from a variety of other conditions.[1][2][3]
Disease | Mutation | Etiology | Symptoms | Signs | laboratory data | Treatment | Associated findings | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CBC | Erythropoietin level | PBS | PT/PTT | |||||||||||||||||||
JAK2 mutation | CALR mutation | Fatigue | Headache | Bleeding | Pain | Other symptoms | Appearance | Fever | Tenderness | Splenomegaly | Other signs | Hb | RBC | WBC | Plt | |||||||
Polycythemia vera (PV) | > 95% | Autonomous erythrocyte production | + | - |
|
Ruddy face | - | - | + | NA | ↑ | ↑ RBC mass | Nl to ↑ | Nl to ↑ | ||||||||
Essential thrombocythemia (ET) | 50% | +/- |
|
+ | + (paradoxical) |
|
+ | Bruises | ↑ (dysfunctional platelets) | |||||||||||||
Chronic myeloid leukemia (CML) | - | - |
|
+ | + | + | Abdominal pain | + | + | ↑ | ↑ | ↑ | ↑ | Elevated metamyelocytes and other white blood cells at various stages of maturation |
| |||||||
Primary myelofibrosis (PMF) |
|
+ | + | Abdominal pain |
|
Pallor | + | ↓ | ↓ | ↓ | ↓ |
| ||||||||||
Secondary polycythemia | - | - |
|
+ | + | - | Depends on etiology | Cyanosis | ↑ | ↑ |
|
|
References
- ↑ Tefferi A, Barbui T (2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am J Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
- ↑ Sanchez S, Ewton A (2006). "Essential thrombocythemia: a review of diagnostic and pathologic features". Arch Pathol Lab Med. 130 (8): 1144–50. doi:10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2. PMID 16879015.
- ↑ Jabbour E, Kantarjian H (2014). "Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management". Am J Hematol. 89 (5): 547–56. doi:10.1002/ajh.23691. PMID 24729196.